BidaskClub upgraded shares of ZIOPHARM Oncology (NASDAQ:ZIOP) from a hold rating to a buy rating in a report released on Thursday.
Several other research firms have also issued reports on ZIOP. Zacks Investment Research raised ZIOPHARM Oncology from a hold rating to a buy rating and set a $3.75 price target for the company in a report on Friday, December 7th. Raymond James raised ZIOPHARM Oncology from a market perform rating to an outperform rating and set a $5.00 price target for the company in a report on Thursday, November 15th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $4.92.
NASDAQ:ZIOP traded down $0.01 during mid-day trading on Thursday, hitting $3.51. 33,431 shares of the company traded hands, compared to its average volume of 1,575,504. ZIOPHARM Oncology has a one year low of $1.56 and a one year high of $5.00. The firm has a market capitalization of $563.96 million, a PE ratio of -7.40 and a beta of 2.59.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Featured Story: Trading Strategy Methods and Types
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.